Pharmacokinetics, biodistribution and bi
β
Jacoba G. Tibben; Otto C. Boerman; Leon F. A. G. Massuger; Charles P. T. Schijf;
π
Article
π
1996
π
John Wiley and Sons
π
French
β 856 KB
The bispecific monoclonal antibody (biMAb) OC/TR combines the anti-ovarian-cancer reactivity of the MOvl8 monoclonal antibody (MAb) with the reactivity of an anti-CD3 MAb. Pre-clinical studies have indicated that this biMAb is able to redirect the cytolytic activity of T cells towards tumour cells,